Successful Treatment with Etanercept in a Patient with Adult-onset Still's Disease.
- Author:
Hak WOO
1
;
Ok Ki KIM
;
Gi Hoon LEE
;
Jeong Jin PARK
;
Shin Seok LEE
;
Yong Wook PARK
Author Information
1. Department of Rheumatology, Chonnam National University Medical School, Gwangju, Korea. ppaarrkkyw@empal.com
- Publication Type:Case Report
- Keywords:
Adult onset Still's disease;
Etanercept;
Tumor necrosis factor-alpha
- MeSH:
Antirheumatic Agents;
Cyclosporine;
Cytokines;
Etanercept;
Humans;
Immunoglobulins;
Interleukin-18;
Interleukin-8;
Interleukins;
Prednisolone;
Steroids;
Still's Disease, Adult-Onset*;
Tumor Necrosis Factor-alpha
- From:The Journal of the Korean Rheumatism Association
2006;13(4):306-310
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder of unknown etiology. Non-steroidal anti-inflammatory drugs (NSAIDs), steroids, disease modifying anti-rheumatic drugs (DMARDs), immunosuppressives and intravenous immunoglobulin (IVIG) have been used to control the disease. It was suggested that several pro-inflammatory cytokines, such as interleukin (IL)-6, IL-8, IL-18, and tumor necrosis factor (TNF)-alpha, play an important role in its pathogenesis. Recent reports showed the clinical effectiveness of TNF-alpha blockers (infliximab and etanercept) in refractory AOSD. We report a case successfully treated with etanercept in the early AOSD refractory to the combination therapy of high-dose prednisolone and cyclosporine (CSA).
